TOP 100 MEDICAL SITES
| |||
|
| |||
| |||
|
| |||
| Osiris Therapeutics, Inc. Q1 2010 Earnings Call Transcript Osiris Therapeutics, Inc. (OSIR)Q1 2010 Earnings Call TranscriptMay 7, 2010 9:00 am ETComplete Story » seekingalpha.com |
Antibody Kills 91% of HIV Strains In a significant step toward an AIDS vaccine, U.S. government scientists have discovered three powerful antibodies, the strongest of which neutralizes 91% of HIV strains, more than any AIDS antibody yet discovered. online.wsj.com |
In Many CPRs, Skip Mouth-to-Mouth Two new studies bolster a shift in thinking about how to revive many cardiac-arrest patients: Don't do mouth-to-mouth resuscitation. online.wsj.com |
Cord Blood America Closes Acquisition of BioCells, Inc., Profitable Company and One of South America's Largest Stem Cell Companies [PR Newswire] - Cord Blood America, Inc. , the umbilical cord blood stem cell preservation company focused on bringing the life saving potential of stem cells, a biological insurance policy, to families nationwide and internationally, today announced that it has purchased controlling interest, 50.1 percent, of Biocordcell Argentina S.A. . us.rd.yahoo.com |
Delcath Takeover Rumors Emerge Tim Shaw submits:Unconfirmed takeover rumors emerged on Thursday regarding Bristol-Myers (BMY) and Delcath Systems (DCTH). The general rumor that is being spread is that BMY will acquire DCTH for $15.00 a share. The stock surged 11.88% higher on the rumor.In my original article, Delcath Systems: A Great Buy at These Prices, I estimated a potential target price for DCTH, if approved by the FDA, at approximately $37.00 per share.Complete Story » seekingalpha.com |